ATE259243T1 - Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse - Google Patents

Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse

Info

Publication number
ATE259243T1
ATE259243T1 AT96938773T AT96938773T ATE259243T1 AT E259243 T1 ATE259243 T1 AT E259243T1 AT 96938773 T AT96938773 T AT 96938773T AT 96938773 T AT96938773 T AT 96938773T AT E259243 T1 ATE259243 T1 AT E259243T1
Authority
AT
Austria
Prior art keywords
body mass
lean body
increase lean
obesity protein
increasing
Prior art date
Application number
AT96938773T
Other languages
English (en)
Inventor
Mary Ann Pelleymounter
Christopher Francis Toombs
Michael Benjamin Mann
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE259243T1 publication Critical patent/ATE259243T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96938773T 1995-11-22 1996-11-04 Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse ATE259243T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56173295A 1995-11-22 1995-11-22
PCT/US1996/017718 WO1997018833A1 (en) 1995-11-22 1996-11-04 Methods of increasing lean tissue mass using ob protein compositions

Publications (1)

Publication Number Publication Date
ATE259243T1 true ATE259243T1 (de) 2004-02-15

Family

ID=24243198

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96938773T ATE259243T1 (de) 1995-11-22 1996-11-04 Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse
AT02011474T ATE455554T1 (de) 1995-11-22 1996-11-04 Verfahren zur erhöhung der mageren fleischmasse mit fettleibigkeitsprotein (ob) zusammensetzungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02011474T ATE455554T1 (de) 1995-11-22 1996-11-04 Verfahren zur erhöhung der mageren fleischmasse mit fettleibigkeitsprotein (ob) zusammensetzungen

Country Status (15)

Country Link
EP (3) EP1285664B1 (de)
JP (2) JP4173914B2 (de)
AT (2) ATE259243T1 (de)
AU (3) AU7607496A (de)
CA (2) CA2236163A1 (de)
DE (2) DE69631544T2 (de)
DK (1) DK0866720T3 (de)
ES (2) ES2217327T3 (de)
IL (2) IL124442A0 (de)
MX (1) MX9803992A (de)
NZ (3) NZ512083A (de)
PT (1) PT866720E (de)
SI (1) SI0866720T1 (de)
WO (1) WO1997018833A1 (de)
ZA (1) ZA969605B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
ES2217327T3 (es) * 1995-11-22 2004-11-01 Amgen Inc., Proteina ob para aumentar la masa de tejido magro.
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
AU2246097A (en) * 1996-01-25 1997-08-20 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
EP0917469A1 (de) * 1996-04-19 1999-05-26 ZymoGenetics, Inc. Verfahren zur induzierung der knochenbildung
CA2274799A1 (en) * 1996-12-20 1998-07-02 Eli Lilly And Company Anti-obesity proteins
EA004790B1 (ru) * 1996-12-20 2004-08-26 Амген Инк. Композиции на основе слитого белка ов и способы их применения
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
EP0950417A3 (de) 1998-02-23 2000-02-23 Pfizer Products Inc. Behandlung von Skeletterkrankungen
WO1999053939A1 (en) * 1998-04-20 1999-10-28 Mayo Foundation For Medical Education And Research Treatment of osteoporosis with leptin
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
WO2000024418A1 (en) * 1998-10-27 2000-05-04 Eli Lilly And Company Prevention of muscle mass loss with leptin receptor ligands
WO2000047741A1 (en) * 1999-02-12 2000-08-17 Amgen Inc. Glycosylated leptin compositions and related methods
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
DK1444516T3 (da) 2001-10-22 2010-11-15 Amgen Inc Anvendelse af leptin til behandling af lipoatrofi hos mennesker og fremgangsmåde til at bestemme en prædisposition for denne behandling
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
ES2390082T5 (es) * 2004-06-30 2018-01-19 Nektar Therapeutics Conjugados de resto de Factor IX y polímeros
ES2325773T5 (es) 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
WO2008048691A2 (en) * 2006-10-18 2008-04-24 Amylin Pharmaceuticals, Inc. Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
ES2630031T3 (es) 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
LT2900230T (lt) 2012-09-27 2019-01-10 The Children`S Medical Center Corporation Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai
TR201901299T4 (tr) 2013-11-26 2019-02-21 Childrens Medical Ct Corp Obezite tedavisine yönelik bileşikler ve bunların kullanım yöntemleri.
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
PT3509624T (pt) 2016-09-12 2023-08-28 Amryt Pharmaceuticals Inc Métodos de deteção de anticorpos neutralizantes anti-leptina

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1228925B (it) * 1987-08-07 1991-07-10 Eniricerche Spa Procedimento per la preparazione dell'ormone della crescita umano
DK173142B1 (da) * 1988-08-24 2000-02-07 Natinco Nv Fremgangsmåde til forbedring af kødkvaliteten og foderomsætningseffektiviteten for grise
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
DE4428146A1 (de) * 1993-08-13 1995-02-16 Putzmeister Maschf Verfahren und Anordnung zur Oberflächenbearbeitung von Großobjekten
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
ES2217327T3 (es) * 1995-11-22 2004-11-01 Amgen Inc., Proteina ob para aumentar la masa de tejido magro.
RU2178307C2 (ru) * 1995-12-27 2002-01-20 Джинентех Инк. Производные ов-протеина
EA004790B1 (ru) * 1996-12-20 2004-08-26 Амген Инк. Композиции на основе слитого белка ов и способы их применения
CA2286098C (en) * 1997-04-17 2009-07-07 Amgen Inc. Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods

Also Published As

Publication number Publication date
JP4227325B2 (ja) 2009-02-18
EP1285664A2 (de) 2003-02-26
ES2217327T3 (es) 2004-11-01
JP4173914B2 (ja) 2008-10-29
EP0956862A1 (de) 1999-11-17
ES2339846T3 (es) 2010-05-26
PT866720E (pt) 2004-06-30
AU763755B2 (en) 2003-07-31
ATE455554T1 (de) 2010-02-15
NZ512083A (en) 2003-02-28
EP1285664B1 (de) 2010-01-20
NZ511617A (en) 2003-08-29
JP2002206000A (ja) 2002-07-23
DE69631544D1 (de) 2004-03-18
DK0866720T3 (da) 2004-06-14
EP1285664A3 (de) 2003-07-30
NZ527007A (en) 2005-01-28
ZA969605B (en) 1997-06-02
CA2358862A1 (en) 1997-05-29
WO1997018833A1 (en) 1997-05-29
DE69638119D1 (de) 2010-03-11
EP0866720B1 (de) 2004-02-11
DE69631544T2 (de) 2004-12-23
EP0866720A1 (de) 1998-09-30
AU4265300A (en) 2000-09-07
JP2000500492A (ja) 2000-01-18
MX9803992A (es) 1998-09-30
AU4265200A (en) 2000-09-21
AU763769B2 (en) 2003-07-31
IL127926A (en) 2006-08-20
CA2236163A1 (en) 1997-05-29
AU7607496A (en) 1997-06-11
SI0866720T1 (en) 2004-10-31
IL124442A0 (en) 1998-12-06
IL127926A0 (en) 1999-11-30

Similar Documents

Publication Publication Date Title
ATE259243T1 (de) Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse
EA200300845A1 (ru) Модифицированные антитела и способы применения
DK0733067T3 (da) N-terminalt kemisk modificerede proteinpræparater og fremgangsmåder
ATE178907T1 (de) Rezeptorbindende region des diphtherietoxius
RO117177B1 (ro) Proteine recombinante, anti-obezitate, murine şi umane, secvenţă adn, care le codifică, procedeu de producere a proteinei şi conjugat cu acestea
EA200000298A1 (ru) Агонисты простагландинов и их применение для лечения заболеваний костей
BR9915679A (pt) Composições e métodos para aumentar a mineralização óssea
ATE458815T1 (de) Homologe des nogo rezeptors
ATE267255T1 (de) Ob proteinderivate mit verlängerter halbwertzeit
BR9508467A (pt) Composição de matéria peptídeo de ligação de receptor de somatostatina composição farmacéutica e processo para realizar uma cirurgia guiada por radiosótopos ou um procedimento de radiodiagnóstico ou radioterapéutico e para aliviar uma doença relacionada com somatostetina em um animal
HUP9901688A3 (en) Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
PT804562E (pt) Factor 2 de crescimento de tecido conjuntivo
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
DE69010294T2 (de) Verwendung von Antiprogestomimetika zur Stimulierung des Eisprungs.
DE69735039D1 (de) Acetylhydrolase des Plättchen aktivierenden Faktors, und entsprechendes Gen
SE9803962D0 (sv) Nucleic acid encoding a nervous tissue sodium channel
ATE165594T1 (de) Triarylethylenderivate zur therapeutischen verwendung
AU7079300A (en) Compositions and methods for the treatment of immune related diseases
MD899G2 (ro) Procedeu de activizare a osteogenezei reparatorii

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0866720

Country of ref document: EP